RxDoctor Payments Data

Philip Niles, MD

Retina Specialist · Williamsville, NYNPI 1609136126

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,604 of the $29,845 with a category attached, or 85.8%. Regeneron Healthcare Solutions, Inc. accounts for 83.1% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $7,827, more than ten times the $662 reported in 2019. Among retina specialist clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,845in general payments, 2019–2025

Across 82 payments — averaging $363.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$25K
  • Regeneron$2K
  • Alimera Sciences, Inc.$1K
  • Genentech USA, Inc.$458
  • Apellis Pharmaceuticals, Inc.$359
  • Alcon$343
  • plus $810 from 9 others

What the payments were for

  • Consulting fees$25,60486%
  • Speaking & faculty fees$1,2004%
  • Food & beverage$3,02410%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,845 in reported general payments places this provider in the 90th percentile of 99 retina specialist providers in New York.

See all retina specialist providers in New York

Medicare billing

Part B allowed, 2024
$2,460,752
Medicare patients
778
Services billed
31,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate361$12,149
IlevroNepafenac19$9,219
MoxifloxacinMoxifloxacin Hcl139$3,082
Ketorolac Tromethamine111$1,928
Atropine Sulfate39$1,798
Timolol Maleate22$780
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$696
Brimonidine Tartrate24$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$254$9,21919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 99 retina specialist providers in New York.

Other retina specialist in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →